Listen To The Lancet Gastroenterology & Hepatology

Hannes Hagström discusses a study investigating the feasibility of screening for advanced liver fibrosis alongside retina scanning in people with type 2 diabetes.

Cathy Lu (University of Calgary) discusses a consensus statement on the use of intestinal ultrasound for assessing and monitoring small bowel strictures in Crohn's disease.

Peter De Cruz (University of Melbourne) discusses the PREDICT-UC trial of intensified versus standard dose infliximab induction therapy for steroid-refractory acute severe ulcerative colitis.

Shahida Din (Western General Hospital, Edinburgh) and Beatriz Gros (Reina Sofía University Hospital, Cordoba) discuss two new papers on the harms associated with receiving placebo in induction and maintenance trials of biological therapies and small molecules in inflammatory bowel disease.

Arndt Vogel (Toronto General Hospital) discusses the NALIRICC trial of nanoliposomal irinotecan added to fluorouracil plus leucovorin in patients with cholangiocarcinoma and gallbladder carcinoma previously treated with gemcitabine-based therapies.

Nancy Baxter (University of Melbourne) discusses a population-based study on the duration of risk reduction in colorectal cancer incidence and mortality after a complete colonoscopy.

Sanna Nybacka and Magnus Simrén (University of Gothenburg) discuss the CARIBS randomised controlled trial of a low FODMAP diet versus a low-carbohydrate diet versus pharmacological treatment in IBS.

Nuru Noor (University of Cambridge) discusses the PROFILE trial of biomarker-stratified treatment strategies in people with newly diagnosed Crohn's disease.

Yusuke Shimakawa (Institut Pasteur) discusses the development and evaluation of a simple score for hepatitis B treatment eligibility in Africa.

Mads Israelsen (Odense University Hospital) discusses a study to validate the new nomenclature of steatotic liver disease in patients with a history of excessive alcohol intake.

Louise Dye (University of Leeds) discusses a trial exploring the role of expectancy and gluten ingestion on symptoms in people with non-coeliac gluten sensitivity.

Tzu-Chan Hong (National Taiwan University Cancer Centre) discusses a systematic review and meta-analysis on primary antibiotic resistance of Helicobacter pylori between 1990 and 2022 in the Asia-Pacific region.

Sarah Moen (Erasmus University Medical Center) discusses a retrospective cohort study examining the risk of metachronous colorectal cancer after partial or extensive colectomy in carriers of different pathogenic Lynch syndrome variants.

Anna Emilie Kann (Zealand University Hospital, Denmark) discusses a population-based study done in Denmark exploring the causes of mortality in patients with alcohol-related liver disease.

Robert Krouse (University of Pennsylvania) discusses the pragmatic S1316 trial of surgical versus non-surgical management for patients with malignant small bowel obstruction.

Marc Rothenberg (University of Cincinnati College of Medicine) discusses a new trial assessing the efficacy and safety of benralizumab in patients with eosinophilic gastritis, and how the surprising findings might change our understanding of eosinophilic gastrointestinal diseases.

Michael Pavlides (University of Oxford) discusses work by the LITMUS Consortium on the prognostic performance of non-invasive tests in patients with non-alcoholic fatty liver disease.

Jasmohan Bajaj (Virginia Commonwealth University and Central Virginia Veterans Healthcare System, Richmond, VA, USA), on behalf of the CLEARED Consortium, discusses a prospective observational cohort study examining global disparities in mortality and liver transplantation in hospitalised patients with cirrhosis.

Adelina Artenie (University of Bristol, UK) discusses a systematic review and meta-analysis exploring the incidence of HIV and HCV among people who inject drugs, and associations with age and sex or gender.

Johan Burisch (Copenhagen University Hospital, Denmark) discusses the findings and recommendations of The Lancet Gastroenterology & Hepatology Commission on the cost of inflammatory bowel disease in high-income settings.